Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FOR46
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : FibroGen
Deal Size : $200.0 million
Deal Type : Licensing Agreement
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
Details : The collaboration expands FibroGen’s clinical pipeline with potential first-in-class product candidate, FOR46, a potential first-in-class Phase 1 ADC targeting a novel epitope on CD46, being developed for the treatment of metastatic castration-resistan...
Brand Name : FOR46
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 08, 2023
Lead Product(s) : FOR46
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : FibroGen
Deal Size : $200.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?